Drug Profile


Alternative Names: EPO 906; Epothilone B

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Novartis
  • Class Antineoplastics; Epothilones
  • Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Brain cancer; Breast cancer; Colorectal cancer; Hepatocellular carcinoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 30 Sep 2012 Novartis completes a phase II trial in Prostate cancer (Hormone-refractory, Metastatic disease) in Australia, Belgium, France, Germany, Italy, Singapore, Spain and USA (NCT00411528)
  • 13 Jun 2012 Novartis completes a phase I trial of patupilone in combination with everolimus in Solid tumours (refractory disease) in USA (NCT00496600)
  • 27 Aug 2011 Novartis completes a phase I trial in late-stage solid tumours in US (NCT00420524)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top